MedPath
HSA Approval

SEMERIN COUGH SYRUP

SIN03526P

SEMERIN COUGH SYRUP

SEMERIN COUGH SYRUP

May 25, 1989

CENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

CENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantCENTRAL CHEMICAL & ENTERPRISES PTE. LTD.
Licence HolderCENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05CA10

combinations

Manufacturer Information

CENTRAL CHEMICAL & ENTERPRISES PTE. LTD.

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Active Ingredients

SODIUM CITRATE

150 mg/5 ml

Sodium citrate

EPHEDRINE HCl

4 mg/5 ml

Ephedrine

AMMONIUM CHLORIDE

100 mg/5 ml

Ammonium chloride

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SEMERIN COUGH SYRUP - HSA Approval | MedPath